HYP-6589
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HYP-6589, covering 2025-12-23 to 2025-12-23. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes [Phase 1, Phase 2]